2022-05-16
From May 13 to 15,2022, the Office of Veterinary Drug GMP Working Committee of Guangdong Provincial Department of Agriculture and Rural Affairs appointed a GMP expert group for veterinary drug acceptance inspection to carry out the new on-site inspection and acceptance of veterinary drug GMP of Guangdong writing's Dahuanong Biotechnology Co., LTD. (hereinafter referred to as "Animal Protection Factory").
The
meeting site
The expert team, after listening to the report on the implementation and operation of the new version of the veterinary GMP at the Animal Health Products Factory, conducted a comprehensive inspection of 15 production lines including granules (including traditional Chinese medicine extraction), powders (including traditional Chinese medicine extraction), powders/premixes, premix, oral solutions, oral solutions (traditional Chinese medicine extraction), terminal sterilization intramammary infusions (including traditional Chinese medicine extraction), terminal sterilization small volume injectables (including traditional Chinese medicine extraction), terminal sterilization large volume non-intravenous injectables (including traditional Chinese medicine extraction), non-terminal sterilization large volume injectables, powder injections, disinfectants (solid), and disinfectants (liquid). The inspection was based on the new veterinary GMP standards. Additionally, in conjunction with the actual production of products, the team assessed the production, testing, and key personnel positions for on-site operation, national regulations, equipment and facility management, and quality management documentation assessments. Through a comprehensive evaluation, the factory (Sino-Foreign Pharmaceutical Company) was recommended to have 15 production lines that comply with the new veterinary GMP standards.
Director Lin Haidan of the Provincial Agricultural Product Quality and Safety Center pointed out that Dahuanong Animal Health Products Factory has many production lines and a large production capacity. It should fully utilize its capacity to increase both volume and revenue during the industry's downturn. The factory should leverage its platform, personnel, equipment, and technological advantages to accelerate the development and cooperation of new veterinary drugs. As a leading enterprise, the factory should share its successful experiences, lead the industry's development, and contribute to the healthy and high-quality development of the industry.
Chen Ruiai, the Chief Operating Officer of Wenshi Foodstuffs Group and the Chairman of DaHua Agricultural, pointed out that the Animal Health Products Factory should seriously carry out rectifications according to the requirements of leaders and experts, and play a leading role in contributing to the high-quality development of the industry. Firstly, it should continue to strengthen the learning and training of the new veterinary GMP standards to standardize equipment, document records, and personnel operations, comprehensively enhance GMP awareness and product quality, and achieve high-quality development. Secondly, it should adopt more innovative thinking and participate more in technical cooperation with peer enterprises, using the advantages of a complete range of products and multiple production lines to complement each other's development and accelerate growth. Thirdly, it should leverage its quality and scale advantages to provide safe veterinary drugs, provide security for the breeding industry, and contribute to the increase of Guangdong Province's animal health industry.
The smooth passing of this acceptance marks a new level in the production capacity and GMP management level of the Animal Health Products Factory, further enhancing the company's ability to serve domestic and international customers. The company will deepen the quality management to provide more high-quality, efficient, and safe products for the breeding industry.